Evasion of CD8+ T Cells is Critical for Superinfection by Cytomegalovirus

Overview

Journal Science

Specialty Science

Date 2010 Apr 3

PMID 20360110

Citations 163

Authors

Scott G Hansen

Colin J Powers

Rebecca Richards

Abigail B Ventura

Julia C Ford

Don Siess

Michael K Axthelm

Jay A Nelson

Michael A Jarvis

Louis J Picker

Klaus Fruh

Affiliations

Soon will be listed here.

Abstract

Cytomegalovirus (CMV) can superinfect persistently infected hosts despite CMV-specific humoral and cellular immunity; however, how it does so remains undefined. We have demonstrated that superinfection of rhesus CMV-infected rhesus macaques (RM) requires evasion of CD8+ T cell immunity by virally encoded inhibitors of major histocompatibility complex class I (MHC-I) antigen presentation, particularly the homologs of human CMV US2, 3, 6, and 11. In contrast, MHC-I interference was dispensable for primary infection of RM, or for the establishment of a persistent secondary infection in CMV-infected RM transiently depleted of CD8+ lymphocytes. These findings demonstrate that US2-11 glycoproteins promote evasion of CD8+ T cells in vivo, thus supporting viral replication and dissemination during superinfection, a process that complicates the development of preventive CMV vaccines but that can be exploited for CMV-based vector development.

Citing Articles

Rhesus Cytomegalovirus-encoded Fcγ-binding glycoproteins facilitate viral evasion from IgG-mediated humoral immunity.

Otero C, Petkova S, Ebermann M, Taher H, John N, Hoffmann K Nat Commun. 2025; 16(1):1200.

PMID: 39885150 PMC: 11782611. DOI: 10.1038/s41467-025-56419-3.

Cytomegalovirus Genetic Diversity and Evolution: Insights into Genotypes and Their Role in Viral Pathogenesis.

Venturini C, Breuer J Pathogens. 2025; 14(1).

PMID: 39861011 PMC: 11768282. DOI: 10.3390/pathogens14010050.

Human cytomegalovirus UL18 prevents priming of MHC-E- and MHC-II-restricted CD8 T cells.

Malouli D, Taher H, Mansouri M, Iyer R, Reed J, Papen C Sci Immunol. 2024; 9(100):eadp5216.

PMID: 39392895 PMC: 11797217. DOI: 10.1126/sciimmunol.adp5216.

Specific targeting of cancer vaccines to antigen-presenting cells via an endogenous TLR2/6 ligand derived from cysteinyl-tRNA synthetase 1.

Kim H, Cho S, Kim S, Song E, Jung W, Shin Y Mol Ther. 2024; 32(10):3597-3617.

PMID: 39066478 PMC: 11489552. DOI: 10.1016/j.ymthe.2024.07.014.

Vaccine adjuvants for infectious disease in the clinic.

Goetz M, Thotathil N, Zhao Z, Mitragotri S Bioeng Transl Med. 2024; 9(4):e10663.

PMID: 39036089 PMC: 11256182. DOI: 10.1002/btm2.10663.

References

Meyer-Konig U, Ebert K, Schrage B, Pollak S, Hufert F . Simultaneous infection of healthy people with multiple human cytomegalovirus strains. Lancet. 1998; 352(9136):1280-1. DOI: 10.1016/S0140-6736(05)70487-6. View

Hansen S, Vieville C, Whizin N, Coyne-Johnson L, Siess D, Drummond D . Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med. 2009; 15(3):293-9. PMC: 2720091. DOI: 10.1038/nm.1935. View

Adler S, Starr S, Plotkin S, Hempfling S, Buis J, Manning M . Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis. 1995; 171(1):26-32. DOI: 10.1093/infdis/171.1.26. View

Boppana S, Rivera L, Fowler K, Mach M, Britt W . Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J Med. 2001; 344(18):1366-71. DOI: 10.1056/NEJM200105033441804. View

Powers C, DeFilippis V, Malouli D, Fruh K . Cytomegalovirus immune evasion. Curr Top Microbiol Immunol. 2008; 325:333-59. DOI: 10.1007/978-3-540-77349-8_19. View

Powers C, Fruh K . Signal peptide-dependent inhibition of MHC class I heavy chain translation by rhesus cytomegalovirus. PLoS Pathog. 2008; 4(10):e1000150. PMC: 2542416. DOI: 10.1371/journal.ppat.1000150. View

Furman M, Dey N, Tortorella D, Ploegh H . The human cytomegalovirus US10 gene product delays trafficking of major histocompatibility complex class I molecules. J Virol. 2002; 76(22):11753-6. PMC: 136774. DOI: 10.1128/jvi.76.22.11753-11756.2002. View

Hewitt E, Gupta S, Lehner P . The human cytomegalovirus gene product US6 inhibits ATP binding by TAP. EMBO J. 2001; 20(3):387-96. PMC: 133477. DOI: 10.1093/emboj/20.3.387. View

Walter E, Greenberg P, Gilbert M, Finch R, Watanabe K, Thomas E . Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995; 333(16):1038-44. DOI: 10.1056/NEJM199510193331603. View

10.

Pass R, Zhang C, Evans A, Simpson T, Andrews W, Huang M . Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med. 2009; 360(12):1191-9. PMC: 2753425. DOI: 10.1056/NEJMoa0804749. View

11.

Liu Z, Winkler M, Biegalke B . Human cytomegalovirus: host immune modulation by the viral US3 gene. Int J Biochem Cell Biol. 2008; 41(3):503-6. DOI: 10.1016/j.biocel.2008.10.012. View

12.

Tirabassi R, Ploegh H . The human cytomegalovirus US8 glycoprotein binds to major histocompatibility complex class I products. J Virol. 2002; 76(13):6832-5. PMC: 136258. DOI: 10.1128/jvi.76.13.6832-6835.2002. View

13.

Selin L, Brehm M, Naumov Y, Cornberg M, Kim S, Clute S . Memory of mice and men: CD8+ T-cell cross-reactivity and heterologous immunity. Immunol Rev. 2006; 211:164-81. PMC: 7165519. DOI: 10.1111/j.0105-2896.2006.00394.x. View

14.

Pande N, Powers C, Ahn K, Fruh K . Rhesus cytomegalovirus contains functional homologues of US2, US3, US6, and US11. J Virol. 2005; 79(9):5786-98. PMC: 1082751. DOI: 10.1128/JVI.79.9.5786-5798.2005. View

15.

Gorman S, Harvey N, Moro D, Lloyd M, Voigt V, Smith L . Mixed infection with multiple strains of murine cytomegalovirus occurs following simultaneous or sequential infection of immunocompetent mice. J Gen Virol. 2006; 87(Pt 5):1123-1132. DOI: 10.1099/vir.0.81583-0. View

16.

Pinto A, Hill A . Viral interference with antigen presentation to CD8+ T cells: lessons from cytomegalovirus. Viral Immunol. 2005; 18(3):434-44. DOI: 10.1089/vim.2005.18.434. View

17.

Sylwester A, Mitchell B, Edgar J, Taormina C, Pelte C, Ruchti F . Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med. 2005; 202(5):673-85. PMC: 2212883. DOI: 10.1084/jem.20050882. View

18.

Krmpotic A, Messerle M, Crnkovic-Mertens I, Polic B, Jonjic S, Koszinowski U . The immunoevasive function encoded by the mouse cytomegalovirus gene m152 protects the virus against T cell control in vivo. J Exp Med. 1999; 190(9):1285-96. PMC: 2195686. DOI: 10.1084/jem.190.9.1285. View

19.

Plotkin S, Starr S, Friedman H, Gonczol E, WEIBEL R . Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge. J Infect Dis. 1989; 159(5):860-5. DOI: 10.1093/infdis/159.5.860. View

20.

Van der Wal F, Kikkert M, Wiertz E . The HCMV gene products US2 and US11 target MHC class I molecules for degradation in the cytosol. Curr Top Microbiol Immunol. 2002; 269:37-55. DOI: 10.1007/978-3-642-59421-2_3. View